Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 173 results for "lacosamide"

Marksans gets USFDA approval and other top pharma news
India Infoline

New and Generic Drug Approvals: Vimpat

Drug Name(s) VIMPAT FDA Application No. (NDA) 022253 Active Ingredient(s) LACOSAMIDE Company UCB INC Original Approval or Tentative Approval Date October 28, 2008 Chemical Type 1New molecular entity (NME) Review Classification ... U.S. Food and Drug Administration, 2 weeks ago
PHARMA-ALEMBIC PHARMA-USFDA NOD United News of India, 3 weeks ago
[x]  

7 images for lacosamide

Money Control, 3 weeks ago
India Infoline, 3 weeks ago
Monthly Prescribing Reference, 1 month ago
Central Chronicle, 3 weeks ago
Money Control, 3 weeks ago
Moneycontrol.com, 3 weeks ago
India Infoline, 3 weeks ago
DNA

Glenmark receives tentative US FDA approval for lacosamide oral solution

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (US FDA) for its lacosamide oral solution, 10 mg/ml, the generic version of Vimpat Oral Solution, 10 mg/ml of UCB, Inc.
 PharmaBiz2 months ago Glenmark Pharma gets tentative ANDA approval for Lacosamide oral solution  Money Control2 months ago Glenmark Pharma gets tentative USFDA nod for Lacosamide Oral Solution [India Infoline News Service]  Pharmacy Choice2 months ago Glenmark gets tentative nod from USFDA for epilepsy drug  Economic Times2 months ago
[x]  

Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Lacosamide Tablets Vimpat

By a News Reporter-Staff News Editor at Drug Week Breckenridge Pharmaceutical, Inc. announced that Breckenridge and MSN Laboratories Private Limited were granted final approval for their ANDA lacosamide tablets, 50 mg, 100 mg, 150 mg and 200 mg. a ...
 Pharmacy Choice4 days ago Breckenridge Pharmaceutical Announces Final ANDA Approval for Lacosamide Tablets (Vimpat)  FirstWord Pharma2 weeks ago
[x]  

New and Generic Drug Approvals: Lacosamide

Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to
 U.S. Food and Drug Administration2 weeks ago
Monthly Prescribing Reference

Long-Term Lacosamide Given Alone Thwarts Partial-Onset Seizures: Presented at AAN

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 16 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma1 month ago Lacosamide Monotherapy Up to 800mg Safe for Partial-Onset Seizures  Monthly Prescribing Reference1 month ago

Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against UCB's VIMPAT®

NEW YORK , May 23, 2016 /PRNewswire/ -- Today, the U.S. Patent & Trademark Office (PTO) granted Argentum Pharmaceuticals LLC's petition for inter partes review (IPR) against all claims of the sole remaining patent listed as covering UCB Inc.'s ...
 WorldNetDaily19 hours ago Argentum Succeeds In Starting Patent Cancellation Trial Against UCB, Inc.'s VIMPAT  BioSpace5 hours ago ARGENTUM PHARMACEUTICALS : Succeeds in Starting Patent Cancellation Trial Against UCB's VIMPAT®  4 Traders19 hours ago
[x]  

2016 UCB S.A. Healthcare Market Study and Competitive Analysis Report

Publisher's, 'UCB S.A. - Pipeline Review, H1 2016', provides an overview of the UCB S.A. pipeline landscape. The report provides comprehensive information on the therapeutics under development for UCB S.A., complete with analysis by stage of ...
 Empowered News5 days ago UCB First Three Months Interim Report 2016:  FirstWord Pharma4 weeks ago
European Pharmaceutical Review

EMA accepts submission for Zebinix use as a monotherapy for partial-onset seizures

The European Medicines Agency (EMA) has accepted Bial's submission for once-daily epilepsy treatment Zebinix as monotherapy for partial-onset seizures. Bial has announced that the European Medicines Agency (EMA) has accepted its application to ...
 European Pharmaceutical Review6 days ago European Medicines Agency (EMA) Accepts Bial's Submission for Once-daily Epilepsy Treatment Zebinix® (eslicarbazepine acetate) as Monotherapy for Partial-onset Seizures  Sys-Con Media1 week ago
[x]  

Pharmaceutical Newsletter - May 02 to 06, 2016

Top News Singapore court asks Singh brothers to pay Daiichi Rs. 2,562.78 Cr An arbitration court in Singapore has ordered Malvinder Singh and Shivinder Mohan Singh, former owners of Ranbaxy Laboratories Ltd, to pay damages worth INR 2,562.78 ...
 India Infoline2 weeks ago Pharmaceutical Newsletter - March 14 to  India Infoline2 months ago
Financial Express

Aurobindo Pharma shares surge 5% on USFDA approval for epilepsy drug

Aurobindo Pharma shares advanced over 5 per cent on Tuesday after the pharma company announced that it has received US Food & Drug Administration (USFDA) approval for its epilepsy prevention drug Lacosamide.(Reuters) Aurobindo Pharma shares ...
 Financial Express3 weeks ago Aurobindo Pharma gains as Credit Suisse initiates coverage  Economic Times3 weeks ago Aurobindo Pharma shares surge on USFDA approval for epilepsydrug  Yahoo! India3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - lacosamide
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less